Depressed Metabolism

You are browsing the archives of "Cryopreservation."

M22 represents the culmination of decades of work in applied cryobiology by researchers Gregory Fahy , Brian Wowk, and others to develop a vitrification agent that can recover complex organs (such as the kidney) from cryogenic temperatures without ice formation and minimal toxicity. In 2005, M22 was licensed by the patent holder 21st Century Medicine [...]

In 2001 the Alcor Life Extension Foundation licensed its first vitrification agent from the cryobiology research company 21st Century Medicine (21CM) to be used for its neuropatients. The composition of this agent, called B2C, has now been made public on Alcor’s website. The published composition is:
Dimethyl sulfoxide 24.765% w/v
Formamide 17.836%
Ethylene glycol [...]

Because the current generation of vitrification agents permit cryopreservation of the brain without ice formation, the current objective of cryonics research is maintenance of viability of the brain during cryopreservation. The most popular viability assay that has been used in cryonics and cryonics-associated cryobiology research is the potassium/sodium ratio (K+/Na+ ratio). Because the ability [...]

“Cryonics does not involve the freezing of dead people. Cryonics involves placing critically ill patients that cannot be treated with contemporary medical technologies in a state of long-term low temperature care to preserve the person until a time when treatments might be available.”
Read the complete article here.

“Even in the case of advanced Alzheimer’s disease, a person is ultimately not declared dead because of the loss of personhood, but as a consequence of secondary whole brain death or cardiac and respiratory arrest. In essence, today’s medicine routinely prolongs life while allowing destruction of the person but pronounces death, using cardiac criteria, without [...]